Ocugen (OCGN) to Release Quarterly Earnings on Friday

Ocugen (NASDAQ:OCGN - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Friday, May 9th. Analysts expect Ocugen to post earnings of ($0.06) per share for the quarter.

Ocugen (NASDAQ:OCGN - Get Free Report) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($0.05) EPS for the quarter, hitting analysts' consensus estimates of ($0.05). The firm had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. Ocugen had a negative net margin of 532.51% and a negative return on equity of 154.75%. During the same quarter in the previous year, the company posted ($0.03) earnings per share. On average, analysts expect Ocugen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ocugen Stock Performance

Shares of NASDAQ:OCGN traded down $0.05 on Wednesday, reaching $0.66. 2,781,985 shares of the company's stock were exchanged, compared to its average volume of 4,590,989. Ocugen has a fifty-two week low of $0.52 and a fifty-two week high of $2.06. The business's 50-day moving average is $0.66 and its two-hundred day moving average is $0.77. The company has a quick ratio of 2.58, a current ratio of 2.58 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $193.35 million, a price-to-earnings ratio of -3.68 and a beta of 4.21.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Chardan Capital lifted their target price on Ocugen from $6.00 to $7.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. HC Wainwright restated a "buy" rating and set a $8.00 price objective on shares of Ocugen in a research report on Thursday, March 6th.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.